Publikation

Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapy.

Wissenschaftlicher Artikel/Review - 23.12.2022

Bereiche
PubMed
DOI
Kontakt

Zitation
Amstad A, Papagiannoulis E, Scherer A, Rubbert-Roth A, Finckh A, Mueller R, Dudler J, Möller B, Villiger P, Schulz M, Kyburz D. Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapy. Rheumatology (Oxford) 2022; 62:89-97.
Art
Wissenschaftlicher Artikel/Review (Englisch)
Zeitschrift
Rheumatology (Oxford) 2022; 62
Veröffentlichungsdatum
23.12.2022
eISSN (Online)
1462-0332
Seiten
89-97
Kurzbeschreibung/Zielsetzung

JAK Inhibitors (JAKi) are recommended DMARDs for patients with moderate-to-severe RA who failed first-line therapy with methotrexate. There is a lack of data allowing an evidence-based choice of subsequent DMARD therapy for patients who had discontinued JAKi treatment. We aimed to compare the effectiveness of TNF inhibitor (TNFi) therapy vs JAKi vs other mode of action (OMA) biologic DMARD (bDMARD) in RA patients who were previously treated with a JAKi.